BioMarin Pharmaceutical Inc (BMRN) to Hold Q4 2007 Conference Call February 26

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) will hold a conference call on February 26 at 5:00 pm to discuss the fourth quarter earnings for 2007.

BioMarin Pharmaceutical develops and commercializes biopharmaceuticals for medical conditions and serious diseases.  The company portfolio includes two products, Naglazyme and Aldurazyme, as well as numerous product candidates under investigation.

Aldurazyme is marketed in the United States, European Union, Japan and other countries to treat mucopolysaccharidosis I.

The Food and Drug Administration (FDA) granted marketing approval for Orapred ODT in June 2006.  Orapred is a disintegrating tablet form of prednisolone to be taken orally.

The European Commission granted marketing approval for Naglazyme in the European Union January 2006.

For more Conference Call related events or to post your own events, visit:

http://events.finditt.com/Events_List.aspx?catid=12